Why Is Novo Nordisk Suing Eli Lilly, and What Does it Mean for Investors?

GLP-1 drugs for value nonaccomplishment are specified a booming concern that it was inevitable the large manufacturers of these wonderment drugs would yet extremity up successful court.

This week, GLP-1 heavyweight Novo Nordisk (NYSE: NVO) sued the starring GLP-1 drugmaker, Eli Lilly (NYSE: LLY), claiming its tv ads are deceptive due to the fact that they authorities that Lilly's Zepbound is much effectual for value nonaccomplishment than Novo's Wegovy.

Missed Nvidia successful 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" awesome flashed for a little-known chipmaker called Nvidia. For the archetypal clip successful years, that aforesaid "Total Conviction" awesome is flashing for a institution 1/100th the size of Nvidia. Continue »

One specified advertisement by Eli Lilly claims that "in a study," radical utilizing Zepbound mislaid an mean of 50 pounds, portion those utilizing Wegovy mislaid an mean of 33 pounds.

But that survey is outdated, Novo Nordisk claims. A higher dose of Wegovy was approved successful March and launched successful April, according to the Danish drugmaker, and a much caller survey shows that the caller dose accrued mean value nonaccomplishment to 47 pounds.

Novo Nordisk claims that Lilly's advertisements besides marque misleading comparisons successful ads for its diabetes cause Mounjaro versus Novo Nordisk's cause Ozempic.

Novo Nordisk's suit seeks a imperishable injunction forcing Eli Lilly to propulsion the ads, arsenic good arsenic a corrective advertisement campaign. It's besides been reported that Novo Nordisk volition question to retrieve profits it mislaid owed to the advertising, though the magnitude is unspecified.

The damages to Lilly, if awarded, astir apt won't beryllium immense

Considering that the ads Eli Lilly ran comparing the 2 drugs lone became outdated successful April, erstwhile Novo Nordisk brought its higher-dose Wegovy to market, immoderate damages to Eli Lilly, if awarded, would astir apt beryllium immaterial. However, if the New Jersey tribunal wherever the suit is filed forces Eli Lilly to halt the ads, that could beryllium a large triumph for Novo Nordisk.

Investors person intelligibly been favoring Lilly successful the conflict for GLP-1 marketplace share. Shares of Eli Lilly are up astir 50% implicit the past 52 weeks, portion Novo Nordisk's stock terms has plummeted astir 27%.

Tirzepatide, the GLP-1 cause down some Mounjaro and Zepbound, became the world's best-selling cause successful the 3rd 4th of 2025, surpassing Keytruda, a blockbuster immunotherapy cause from pharmaceutical elephantine Merck.

But request for GLP-1 drugs is tremendous and increasing rapidly. The planetary marketplace for obesity medicines reached $66 cardinal successful 2025. Bloomberg predicts it volition deed $120 cardinal by 2030. While Lilly has the larger stock of that market, astir 60% of the U.S. marketplace arsenic of February of this year, determination volition astir apt beryllium plentifulness of opportunities for some companies to ratchet up planetary sales.